Val 108/158 Met Polymorphism and Treatment Response to Aripiprazole in Patients with Acute Schizophrenia

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2018 Jun 29

PMID 29950847

Citations 6

Authors

Haruka Kaneko

Itaru Miura

Keiko Kanno-Nozaki

Sho Horikoshi

Mizuki Hino

Hirooki Yabe

Affiliations

Soon will be listed here.

Abstract

Introduction: The Val 108/158 Met polymorphism (rs4680) may affect treatment response to antipsychotics, as well as metabolism and dynamics of neurotransmitters during the treatment of schizophrenia. We investigated the effects of the Val 108/158 Met polymorphism on treatment response to aripiprazole and plasma monoamine metabolite levels in patients with acute schizophrenia.

Materials And Methods: Forty patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured Positive and Negative Syndrome Scale (PANSS) and plasma levels of homovanillic acid (HVA) and plasma MHPG (3-methoxy-4-hydroxyphenethyleneglycol) at baseline and endpoint. The Val 108/158 Met polymorphism was genotyped with the polymerase chain reaction and restriction fragment length polymorphism.

Results: There were significant genotype-time interactions on PANSS total and general psychopathology scores, with Met/Met genotype showing greater improvement. The response rate to aripiprazole did not differ between Val 108/158 Met genotype groups. We found a significant time effect on plasma MHPG levels, but no time effect on plasma HVA levels or time-genotype interactions in the plasma levels of HVA and MHPG. Although the responder rate did not differ among the 3 genotype groups.

Conclusion: Our results suggest that individuals with the Met/Met genotype had greater improvement in PANSS score after the treatment with aripiprazole. On the other hand, the Val 108/158 Met polymorphism may not induce changes in plasma levels of monoamine metabolites during aripiprazole treatment. Because of the small sample size, further studies are needed to confirm and to extend our results.

Citing Articles

Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes.

Fernandez-Miranda J, Diaz-Fernandez S, Cepeda-Piorno F, Lopez-Munoz F Biomedicines. 2024; 12(1).

PMID: 38255270 PMC: 10813024. DOI: 10.3390/biomedicines12010165.

Genetic profile for dopamine signaling predicts brain functional reactivity to repetitive transcranial magnetic stimulation.

Hong H, Kim R, Song Y, Suh C, Lee H, Lyoo I Eur Arch Psychiatry Clin Neurosci. 2022; 273(1):99-111.

PMID: 35951113 DOI: 10.1007/s00406-022-01436-2.

Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease.

Chen A, Chen L, Kim T, Xiong Q Biomedicines. 2021; 9(6).

PMID: 34200134 PMC: 8228225. DOI: 10.3390/biomedicines9060647.

Long acting aripiprazole influences cognitive functions in recent onset schizophrenia.

Peitl V, Stefanovic M, Orlovic I, Culej J, Rendulic A, Matesic K Psychopharmacology (Berl). 2021; 238(6):1563-1573.

PMID: 33580813 DOI: 10.1007/s00213-021-05788-w.

Association Between the COMT Val158Met Polymorphism and Antipsychotic Efficacy in Schizophrenia: An Updated Meta-Analysis.

Ma J, Zhao M, Zhou W, Li M, Huai C, Shen L Curr Neuropharmacol. 2020; 19(10):1780-1790.

PMID: 33100205 PMC: 8977635. DOI: 10.2174/1570159X18666201023154049.

References

Bishop J, Reilly J, Harris M, Patel S, Kittles R, Badner J . Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology (Berl). 2014; 232(1):145-54. PMC: 4282597. DOI: 10.1007/s00213-014-3649-4. View

Miura I, Kanno-Nozaki K, Hino M, Horikoshi S, Ota T, Mashiko H . Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole. J Clin Psychopharmacol. 2015; 35(3):333-4. DOI: 10.1097/JCP.0000000000000330. View

Andreou D, Soderman E, Axelsson T, Sedvall G, Terenius L, Agartz I . Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis. Behav Brain Funct. 2014; 10:26. PMC: 4123495. DOI: 10.1186/1744-9081-10-26. View

Li T, Sham P, Vallada H, Xie T, Tang X, Murray R . Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet. 1996; 6(3):131-3. DOI: 10.1097/00041444-199623000-00005. View

Zhang J, Lencz T, Malhotra A . D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010; 167(7):763-72. PMC: 2896457. DOI: 10.1176/appi.ajp.2009.09040598. View

Huang E, Zai C, Lisoway A, Maciukiewicz M, Felsky D, Tiwari A . Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. Int J Neuropsychopharmacol. 2016; 19(5). PMC: 4886669. DOI: 10.1093/ijnp/pyv132. View

Watanabe K, Miura I, Kanno-Nozaki K, Horikoshi S, Mashiko H, Niwa S . Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia. Psychiatry Res. 2015; 230(2):419-23. DOI: 10.1016/j.psychres.2015.09.030. View

Kohnke M, Wiatr G, Kolb W, Kohnke A, Schick S, Lutz U . Plasma homovanillic acid: a significant association with alcoholism is independent of a functional polymorphism of the human catechol-O-methyltransferase gene. Neuropsychopharmacology. 2003; 28(5):1004-10. DOI: 10.1038/sj.npp.1300107. View

Pelayo-Teran J, Perez-Iglesias R, Vazquez-Bourgon J, Mata I, Carrasco-Marin E, Vazquez-Barquero J . Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res. 2010; 185(1-2):286-9. DOI: 10.1016/j.psychres.2010.06.006. View

10.

Maas J, Hattox S, Greene N, Landis D . Estimates of dopamine and serotonin synthesis by the awake human brain. J Neurochem. 1980; 34(6):1547-9. DOI: 10.1111/j.1471-4159.1980.tb11240.x. View

11.

Williams G, Castner S . Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience. 2005; 139(1):263-76. DOI: 10.1016/j.neuroscience.2005.09.028. View

12.

Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D . Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol Rep. 2012; 64(3):528-35. DOI: 10.1016/s1734-1140(12)70848-4. View

13.

Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N . Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003; 3(6):356-61. DOI: 10.1038/sj.tpj.6500211. View

14.

Arranz M, Munro J, Sham P, Kirov G, Murray R, Collier D . Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998; 32(2):93-9. DOI: 10.1016/s0920-9964(98)00032-2. View

15.

Zalsman G, Huang Y, Harkavy-Friedman J, Oquendo M, Ellis S, Mann J . Relationship of MAO-A promoter (u-VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of caucasians: A preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2004; 132B(1):100-3. DOI: 10.1002/ajmg.b.30094. View

16.

Woodward N, Jayathilake K, Meltzer H . COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res. 2006; 90(1-3):86-96. DOI: 10.1016/j.schres.2006.10.002. View

17.

Baker K, Baldeweg T, Sivagnanasundaram S, Scambler P, Skuse D . COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol Psychiatry. 2005; 58(1):23-31. DOI: 10.1016/j.biopsych.2005.03.020. View

18.

Jonsson E, Goldman D, Spurlock G, Gustavsson J, Nielsen D, Linnoila M . Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci. 1997; 247(6):297-302. DOI: 10.1007/BF02922258. View

19.

Weickert T, Goldberg T, Mishara A, Apud J, Kolachana B, Egan M . Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry. 2004; 56(9):677-82. DOI: 10.1016/j.biopsych.2004.08.012. View

20.

Miura I, Takeuchi S, Katsumi A, Mori A, Kanno K, Yang Q . Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. J Clin Psychopharmacol. 2011; 32(1):106-9. DOI: 10.1097/JCP.0b013e31823f87ac. View